Clinical Trials on Plasma Cell Myeloma

Total 35492 results

Centre Hospitalier Universitaire, Amiens

Completed

Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 (LPP)

Multiple Myeloma

France
University of Michigan Rogel Cancer Center
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen

Multiple Myeloma | Plasma Cell Leukemia

United States
Clinical Service, China
307 Hospital of PLA; Chinese PLA General Hospital; Peking University Third Hospital and other collaborators

Unknown

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia (Bortezomib)

Multiple Myeloma | Plasma Cell Leukemia

China
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); The Wayne D. Kuni and Joan E. Kuni Foundation

Completed

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

Diffuse Large B-Cell Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Previously Treated Myelodysplastic Syndrome | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Acute Lymphoblastic Leukemia | Refractory Plasma Cell Myeloma | Recurrent Small Lymphocytic Lymphoma | Refractory... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy

Lymphoma | Leukemia | Anemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
LaNova Medicines Limited

Withdrawn

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Relapsed or Refractory Multiple Myeloma | Other Plasma Cell Diseases
University of California, San Francisco

Completed

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

Refractory Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Plasma Cell Myeloma | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Recurrent... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
St. Bartholomew's Hospital

Unknown

Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States
National Cancer Institute (NCI)

Completed

4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma and Plasma Cell Neoplasm

United States, Italy
Sidney Kimmel Cancer Center at Thomas Jefferson...

Withdrawn

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Multiple Myeloma | Plasma Cell Leukemia

United States
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.

Completed

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

Multiple Myeloma | Plasma Cell Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); The Leukemia and Lymphoma Society

Completed

Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma

Chronic Lymphocytic Leukemia | Plasma Cell Myeloma

United States
Melbourne Health

Recruiting

Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Plasma Cell Myeloma | Non-hodgkin Lymphoma | Leukemia, Lymphoblastic, Acute, L1 | Leukemia, Lymphoblastic, Acute, L2

Australia
OHSU Knight Cancer Institute
National Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...

Terminated

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Malignant Solid Neoplasm | Lymphoma | Plasma Cell Myeloma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

PS-341 in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Swiss Group for Clinical Cancer Research

Completed

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Mature T-cell and Nk-cell Neoplasms

Switzerland
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma

Multiple Myeloma | Plasma Cell Myeloma | Precancerous Condition

United States
Barbara Ann Karmanos Cancer Institute

Completed

DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer

Chronic Lymphocytic Leukemia | Plasma Cell Myeloma | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma | Plasma Cell Myeloma

United States
Baptist Health South Florida

Active, not recruiting

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Myeloid Malignancy | Lymphoid Leukemia, Acute | Plasma Cell Tumor

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Frequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Caregivers

Advanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent Leukemia

United States
MedImmune LLC

Completed

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Diffuse Large B-cell Lymphoma

United States, France, Korea, Republic of
Celgene

Withdrawn

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Neoplasms | Hematologic Diseases | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Therapeutic Uses | Plasma Cells
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
European Organisation for Research and Treatment...

Unknown

Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

France, Belgium, Netherlands, Germany, Italy
Senesco Technologies, Inc.

Unknown

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Multiple Myeloma | Plasma Cell Leukemia | Multiple Myeloma in Relapse | Mantle Cell Lymphoma in Relapse | Diffuse Large B Cell Lymphoma in Relapse | Other B Cell Lymphoma in Relapse

United States, South Africa
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Non-Hodgkin Lymphoma | Relapsed or Refractory Chronic Lymphocytic Leukemia

United Kingdom, Spain, France, Australia
California Cancer Consortium
National Cancer Institute (NCI)

Completed

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

Lymphoma | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Personalized NK Cell Therapy in CBT

Recurrent Hodgkin Lymphoma | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Myelodysplastic Syndrome... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Acute Myeloid Leukemia | Recurrent Hodgkin Lymphoma | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Aplastic Anemia | Recurrent Non-Hodgkin... and other conditions

United States
Virginia Commonwealth University
Massey Cancer Center

Completed

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Recurrent Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Plasma... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Myeloma, Multiple | Myeloma-Multiple

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Recurrent Hodgkin Lymphoma | Recurrent Adult Acute Myeloid Leukemia | Recurrent Mantle Cell Lymphoma | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood... and other conditions

United States
University of Maryland, Baltimore

Completed

Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore
University of Maryland Greenebaum Cancer Center

Completed

Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland, Baltimore

Completed

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy

Lymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Lymphoproliferative Disorder

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Chemotherapy Plus Biological Therapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

Lymphoma | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Rochester

Completed

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States

Clinical Trials on Plasma Cell Myeloma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations